We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Interview · April 02, 2015

Interview With Dr. Tony Luongo: The Changing Space of Castrate-Resistant Prostate Cancer

Interview by
Zachary L Smith MD
Interview with
Tony Luongo MD, FRCSC, FACS

 

Additional Info

  1. Sweeney C, Chen Y-H, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Paper presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract LBA2. J Clin Oncol 32:5s, 2014 (suppl; abstr LBA2).

  2. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
  3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.

Disclosure statements are available on the authors' profiles:

Further Reading